Therapies targeting PD-1 cause an imbalance in regulatory T lymphocytes, generating pathological autoantibodies, such as anti-CD74, which is increased in patients with pneumonitis, stimulating the release of inflammatory mediators and suggesting a possible role of antibodies in CIP [4,5]. Here, PDCD1 is linked to pneumonitis.